{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:03:42Z","timestamp":1792292622361,"version":"4.4.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.rmed.2021.106442","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T04:45:39Z","timestamp":1619844339000},"page":"106442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia: Subanalysis from a randomized controlled trial"],"prefix":"10.1016","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7119-5034","authenticated-orcid":false,"given":"Manjunath P.","family":"Pai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5682-9200","authenticated-orcid":false,"given":"Surya","family":"Chitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"McGovern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2021.106442_bib1","series-title":"Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018, NCHS Data Br. No. 360","author":"Hales","year":"2020"},{"key":"10.1016\/j.rmed.2021.106442_bib2","article-title":"Concordance of early and late endpoints for community-acquired bacterial pneumonia trials","author":"Bart","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.rmed.2021.106442_bib3","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.ijid.2010.09.011","article-title":"The obesity paradox in community-acquired bacterial pneumonia","volume":"15","author":"Corrales-Medina","year":"2011","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.rmed.2021.106442_bib4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1183\/09031936.00115312","article-title":"Obesity is associated with improved survival in community-acquired pneumonia","volume":"42","author":"Singanayagam","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2021.106442_bib5","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/jac\/dkw324","article-title":"Information provision for antibacterial dosing in the obese patient: a sizeable absence?","volume":"71","author":"Boyd","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.rmed.2021.106442_bib6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2021.106442_bib7","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1093\/jac\/dkr282","article-title":"Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients","volume":"66","author":"Kees","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.rmed.2021.106442_bib8","article-title":"The effects of obesity on the comparative effectiveness of linezolid and vancomycin in suspected methicillin-resistant Staphylococcus aureus pneumonia","volume":"4","author":"Caffrey","year":"2015","journal-title":"Adv. Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.rmed.2021.106442_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106263","article-title":"Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment","volume":"57","author":"Cornely","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.rmed.2021.106442_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab135","article-title":"Efficacy of omadacycline versus moxifloxacin in the treatment of community\u2010acquired bacterial pneumonia by disease severity: results from the OPTIC study","author":"Ramirez","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.rmed.2021.106442_bib10","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1093\/cid\/ciz397","article-title":"Early clinical response in community-acquired bacterial pneumonia: from clinical endpoint to clinical practice","volume":"69","author":"Ramirez","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.rmed.2021.106442_bib11","series-title":"Am. Soc. Microbiol. Microbe","article-title":"Population pharmacokinetic analyses of omadacycline using Phase 1 and 3 data","author":"Lakota","year":"2018"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611121001487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611121001487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:22:03Z","timestamp":1760617323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611121001487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":12,"alternative-id":["S0954611121001487"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2021.106442","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia: Subanalysis from a randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2021.106442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106442"}}